Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9383510 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL9383513 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL9384392 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL8344263 | 0.81 | MMP2 (0.49) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL20334501 | 0.79 | ADRA1A (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL10038840 | 0.78 | ABL1 (0.40) | MEN1KMT2AALDH1A1GAATSHR | |
| SCHEMBL28705797 | 0.78 | PTGER4 (0.50) | ALDH1A1GAATSHRCPB1 | |
| SCHEMBL9383757 | 0.77 | ALDH1A1 (0.51) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL9388644 | 0.77 | ALDH1A1 (0.51) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL9382299 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AGPR55ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598504-B1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | NEUROTUNE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-8476453-B2 | Process for the preparation of dimiracetam | NEUROTUNE AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2598504-A1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | Neurotune AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123509-A1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | NEUROTUNE AG (CH) | 2013-05-16 | — | — | US | disclosed |
| WO-2012013640-A1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | NEUROTUNE AG (CH) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123509-A1 | PROCESS FOR THE PREPARATION OF DIMIRACETAM | ADH1A, ADH1C, OGDH | MEN1 3257/4885KMT2A 740/4885GPR55 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.